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Abstract
Background: Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are among the most well established
therapies for the treatment of depression. However, some major questions remain unanswered. First, it is unknown what
session frequency results in the most optimal (cost) effectiveness in psychotherapy. Second, the debate as to
what mechanisms underlie the effect of psychotherapy has not yet been resolved. Enhancing knowledge about
the optimal session frequency and mechanisms of change seems crucial in order to optimize the (cost) effectiveness of
psychotherapy for depression. This study aims to compare treatment outcome of twice-weekly versus once-weekly
sessions of CBT and IPT. We expect twice-weekly sessions to be more effective and lead to more rapid recovery
of depressive symptoms in comparison to once-weekly sessions. Both therapy-specific and non-specific process
measures will be included to unravel the mechanisms of change in psychotherapy for depression. Besides the
use of self-reports and behavioral observations, this study will also examine underlying biological processes by
collecting blood samples.
Method: In a multicenter randomized trial, two hundred depressed patients will be recruited from Dutch specialized
mental healthcare centers and randomized into one of the following groups, all receiving a maximum of 20 sessions in
different frequencies: a) twice-weekly sessions at the start of CBT, b) twice-weekly sessions at the start of IPT, c)
once-weekly sessions at the start of CBT, d) once-weekly sessions at the start of IPT. Primary outcome measures
are depression severity, cost-effectiveness and quality of life. Process measures include therapeutic alliance, recall,
therapy-specific skills, motivation and compliance. Assessments will take place during baseline, monthly during
treatment and follow-up at month 9, 12 and 24. In addition, at 12 and 24 months, the frequency of depressive
episodes in the previous year will be assessed. Blood samples will be taken pre- and post-treatment. The study
has been ethically approved and registered.
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Discussion : Finding that twice-weekly sessions are more effective or lead to more rapid recovery of depressive
symptoms could lead to treatment adaptations that have the potential to reduce the personal and societal burden of
depression. In addition, insight into the mechanisms of change and physiological processes in psychotherapy will
enable us to optimize treatments and may help to understand human functioning beyond the context of treatment.
Trial registration: The study has been registered on October 21th, 2014 at the Netherlands Trial Register, part of the
Dutch Cochrane Centre (NTR4856).
Keywords: Depression, Intensity, Change mechanisms, Psychotherapy, Physiology, Multicenter randomized controlled trial
Background
Cognitive (behavioral) therapy (CBT) [1] and interper-
sonal therapy (IPT) [2] are among the most well established
short-term therapies for the treatment of depression. Both
treatments are effective and are recommended as first-
choice treatments [3–6]. However, despite the efficacy and
the acceptance of these therapies among researchers and
clinicians, some major questions remain unanswered. This
study will address two questions about the effectiveness
and change mechanisms of psychotherapy for depression.
First, there is a lack of clarity about the optimal intensity of
psychotherapy [7]. It seems important to know what ses-
sion frequency will provide the most optimal (cost) effect-
iveness in psychotherapy as this could lead to more rapid
recovery and a reduction of direct (e.g. health care) and in-
direct costs (e.g. fewer work-days lost). Second, there are
still many uncertainties regarding how the psychotherapies
actually work. Despite the numerous efforts to understand
the change mechanisms in psychotherapy, this topic re-
mains largely unresolved [8–13]. It is not clear if and to
what extent therapy- specific elements (e.g. cognitive
skills in CBT or relational skills in IPT), non-specific
elements (e.g. therapeutic alliance), or both, contribute
to the effects of psychotherapy. Moreover, there is an
ongoing discussion about what methods are necessary
to conduct a successful study on the mechanisms of
change in psychotherapy [14]. However, when investi-
gating mechanisms of change during psychotherapy it
seems important to not only include patient self-report
measures, but to investigate multiple layers of behavior
(e.g. independent raters, biological measurements) [15].
This study aims to compare treatment outcomes of
twice-weekly versus once-weekly sessions of two widely
used types of psychotherapy: CBT and IPT. Both
therapy- specific and non-specific process measures
will be included to enhance clarity about the mecha-
nisms of change in psychotherapy for depression. In
addition, we will collect blood samples in order to in-
vestigate the (predictive) role of several physiological
processes (e.g. oxytocin, brain-derived neurotrophic
factor, DNA methylation and RNA markers) during the
course of psychotherapy for depression. The main re-
search questions are:
 What is the (cost) effectiveness of twice-weekly
sessions versus once-weekly sessions at the start of
psychotherapy for major depression (CBT or IPT)
over the course of 24 months?
 What change mechanisms may be involved in
mediating the effects of psychotherapy?
Frequency of psychotherapy
Several studies have shown an association between the fre-
quency of therapy sessions and symptom improvement
[16–18]. More specifically, a recent meta-regression found
a strong and positive association between the number of
sessions per week and the effect size of psychotherapy for
adult depression. In that study it was session frequency, in
contrast to the total number of sessions, which was related
to treatment outcome [7]. In routine mental health care,
therapy sessions are commonly planned once a week. The
original CBT manual by Beck does recommend two ses-
sions a week in the beginning of therapy [1]. Most empirical
trials (mostly from the US) have established that CBT is
efficacious providing twice-weekly treatment [19, 20]. How-
ever, Beck’s guidelines have not been followed consistently
and Dutch mental health guidelines do not even give an in-
dication of the frequency of psychotherapy for depression
[6]. Given this gap between recommended and actual prac-
tice, it seems important to investigate whether a higher in-
tensity of treatment will lead to better and more rapid
treatment outcomes and is related to lower rates of relapse.
The question is whether the results of the controlled clin-
ical trials can generalize to clinical practice when an
empirically-supported treatment is not implemented in the
manner in which it was done. Although both conditions
will have the same maximum number of sessions, it is
conceivable that patients in the twice-weekly condition
will respond more quickly and need fewer sessions than
patients in the once-weekly condition. This could lead
to a reduction of both direct (e.g. health care) and indirect
costs (e.g. fewer work-days lost). In addition, differences in
treatment intensity might not only lead to differences in
the length of treatment, number of sessions and a reduc-
tion of costs but also to the activation of different compo-
nents of therapy within different phases of the treatment.
It is possible that some components of therapy will
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become more effective or present when patients receive
sessions twice a week instead of once a week. Further-
more, it will be interesting to see whether therapy type
(CBT vs IPT) moderates the effect of initial session fre-
quency (twice-weekly versus once-weekly). This study will
be the first in the field of depression that directly tests the
hypothesis that twice-weekly sessions lead to better out-
comes than once-weekly sessions. If we find twice-weekly
sessions to be more effective or to lead to more rapid
recovery, this could lead to treatment adaptations that
have the potential to reduce the societal burden of de-
pression. In addition, the question why a particular ses-
sion frequency is more effective than the other might
lead to new directions for understanding change mech-
anisms in psychotherapy.
Mechanisms of change
Nowadays, a broad range of therapies is available for the
treatment of depression. Research points to the equal
effectiveness of different psychotherapies (on average)
and the number of effective psychotherapies seems to
be even expanding [3, 21]. The fact that different psycho-
therapies stemming from different theoretical backgrounds
seem to produce comparable outcomes (on average) raises
the question as to whether the different treatments might
work through common non-specific factors (e.g. thera-
peutic alliance) instead of the therapy-specific techniques
(e.g. change in cognitive skills for CBT or relational skills
for IPT) that are assumed to underlie the effects of a
specific psychotherapies. However, after thirty years of
meta- analyses that tried to support the notion that
treatment efficacy is due to non-specific factors, the
controversy remains [9, 12]. Critics point to the limitations
of a design that includes pre- and post- assessments only,
as if often the case in randomized controlled trials. Several
methodological recommendations have been made to
improve the quality research on change mechanisms in
psychotherapy. First, mediators have to be monitored
across the course of treatment and not only before and
after [10]. The timing of these assessments is critical:
change in the mediator must occur before change in the
outcome in order to rule out reverse causality. To ensure
that the change observed in the mediator was not the result
of a causal path from early change in the outcome variable
to subsequent change in the mediator, the measurement of
the outcome measures should parallel the assessments of
the change mechanisms [11, 13, 22]. Second, the inclusion
of moderators into the research design could lead to new
hypotheses about potential mediators [13, 22]. Third, stud-
ies should make use of more advanced statistical techniques
that are capable of detecting causal mediation. An example
includes growth mixture modeling [10]. This study will
include both potential therapy-specific and non-specific
mechanisms of change. These mechanisms will be mea-
sured after the first two weeks of treatment and once a
month along with the outcome measures. We will in-
clude moderators that are expected to influence the
direction or strength of the relation between the inter-
vention and outcome. Furthermore, in order to analyze
the mechanisms of change we will use a combination of
structural equation modeling (SEM) and multilevel
modeling [23]. In this way, we hope to provide the opti-
mal conditions for detecting mechanisms of change in
psychotherapy for depression within a multicenter ran-
domized trial.
In this study, we hypothesize two pathways of change to
be involved in the course of psychotherapy for depression
(Fig. 1). First, we expect that a higher session frequency
will enhance the quality of the relationship between pa-
tient and therapist. This relationship has been referred to
as therapeutic alliance and involves the behaviors and pro-
cesses within the session, patients’ and therapists’
Fig. 1 Hypothesized pathways of change in psychotherapy for depression
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objectives about therapy and the interpersonal attachment
of mutual trust, confidence and acceptance. Previously,
therapeutic alliance has been positively related to treat-
ment outcome [24–26] while lower therapeutic alliance
was associated with dropout [27]. Possibly, the relation-
ship between patient and therapist will develop more rap-
idly when the contact is more intense. We expect that a
better therapeutic alliance will lead to more patient motiv-
ation and compliance, as the therapist will have better op-
portunities to detect patient’s struggles in motivation and
compliance. Subsequently, higher rates of motivation and
compliance are expected to lead to better and faster treat-
ment outcomes. The second pathway of change focuses
on the process of learning. It is possible that a higher ses-
sion frequency will increase patients’ learning processes
resulting in better treatment outcomes. This seems con-
gruent with previous studies that show that it is the sur-
vival of neurons born in the last five days that is important
for learning [28]. Possibly, a higher frequency will increase
the survival of neurons that are important for learning and
as a consequence optimize learning processes. In this
study, we will measure the degree the patient is able to
recall the content of the previous session and the
therapeutic-specific skills of the patient (e.g. cognitive
therapy skills or interpersonal therapy skills). We expect
that a higher session frequency will lead to better session
recall that, as a consequence, will lead to the development
of better therapy- specific skills. Better therapy-specific
skills are expected to lead to better and faster treatment
outcomes.
Physiological pathways in the course of psychotherapy
for depression
In addition to the focus on self-reports or behavioral obser-
vations for detecting mechanisms of change, this study also
aims to focus on deeper layers of behavior. Earlier studies
showed that a variety of physiological levels are deregulated
in depressed patients and can be restored with use of
antidepressants [29–36]. In this study we will investigate
the role of the brain-derived neurotrophic factor (BDNF)
[30–32], methylation profile of the BDNF gene (e.g. CpG I
and IV) [33, 34] and oxytocin [35, 36] and RNA marker
profiles [37] during psychotherapy for depression. We ex-
pect levels of BDNF and oxytocin to restore during treat-
ment (potential mediators) while the methylation profile of
the BDNF gene (e.g. CpG I and IV) and RNA marker pro-
files might play a role in the prediction of treatment out-
come (prognostic indices) and quite possibly differential
treatment outcome (potential moderators).
Method
Design of the study
We will conduct a multicenter randomized trial with
four parallel groups: a) twice-weekly sessions at the start
of CBT (n = 50), b) twice-weekly sessions at the start of
IPT (n = 50), c) once-weekly sessions at the start of CBT
(n = 50), d) once-weekly sessions at the start of IPT
(n = 50). The anticipated flow of subject enrolment is
graphically shown in Fig. 2. In essence, this is a 2 × 2
factorial design that allows the comparison of fre-
quency type (i.e. twice-weekly vs once-weekly) in the
combined psychotherapy groups (i.e. CBT and IPT) and
vice versa. The Medical Ethics Committee of VU University
Amsterdam approved the study protocol (registration
number 2014.337). The study is registered at the
Netherlands Trial Register, part of the Dutch Cochrane
Centre (NTR4856).
Participants
We aim to include 200 patients that satisfy the following
criteria: a. DSM-IV or DSM-V diagnosis of a major de-
pressive disorder (MDD) (including chronic depression)
or DSM-V diagnosis of a persistent depressive disorder,
b. age > 18 c. the patient is currently not using antide-
pressants or the use of antidepressants has been un-
changed for at least three months before start of
treatment and no change in the use of antidepressants is
planned, d. sufficient knowledge of the Dutch language,
f. score > 19 on Beck’s Depression Inventory II (BDI-II)
[37–39]. Patients will be excluded when a. there is a high
risk of suicide according to the intake staff, b. they are
diagnosed with drug or alcohol dependence, c. they have
a primary diagnosis other than MDD, d. they are diag-
nosed (or suspected) with a cluster A or B personality
disorder during the intake staff, e. they had psychother-
apy (CBT or IPT) focusing on a major depressive dis-
order in the previous year or f. they have no access to
internet facilities. The presence of a depressive disorder
will be indicated by a diagnosis following the Structural
Clinical Interview for DSM-IV Axis I disorders (SCID-I)
[40] or Mini International Neuropsychiatric Interview
Plus (MINI-Plus) [41].
Sample size
Based on the meta-analysis of treatment intensity [7],
we estimate the post-treatment effect size for the differ-
ence in depressive symptoms (BDI-II) between the
main conditions (twice- versus once-weekly in the
combined psychotherapy groups) to be 0.45. Based on
this effect size (alpha = 0.05, power (1-ß) = 0.80, two-
tailed), we need 79 participants per group (e.g. once
versus twice-weekly sessions). Taking 25 % dropout
into account, this means in total at least 200 depressed
patients. The sample size should also suffice to detect
possible interactions of a comparable effect size be-
tween treatment conditions.
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Recruitment
Patients will be recruited in the Dutch specialized mental
healthcare centers including GGZ inGeest (Amsterdam),
Riagg Maastricht (Maastricht), Altrecht (Utrecht) and PsyQ
(Haarlem, The Hague, Leiden). During the intake, patients
will be checked for the in- and exclusion criteria. If patients
are eligible they will be approached for participation in the
study and receive a general information folder. Patients that
cannot participate in the study treatment will receive treat-
ment as usual (Fig. 2).
Randomization and procedure
An independent research assistant will contact eligible
patients one week after the intake procedure in order to
give patients additional study information and to check
if the patient is motivated to participate in the study. If
no structured diagnostic interview has been completed
yet during the intake procedure, the research assistant
will plan a diagnostic interview (SCID-I/MINI). Subse-
quently, if the patient wants to participate and fulfills the
inclusion criteria, the patient will be invited for an on-
line baseline assessment and to sign informed consent.
After the baseline assessment, the patient will be ran-
domized in one of the four groups by using a computer
script performing block randomization (e.g. one- versus
twice weekly; CBT versus IPT). Randomization (patient
level) will be pre-stratified according to severity (high se-
verity = BDI score = > 30; low severity = BDI score < =29)
and treatment site. A venipuncture by experienced
nurses will be planned before the start of treatment. Be-
sides the baseline assessment, the patient will be asked
to complete monthly online assessments in the course of
treatment (month 1–6) and follow-up assessments at
month 9, 12 and 24. This means that the moments of as-
sessment will be equal for each group. In addition, the
therapist and patient will be asked to fulfill some ques-
tionnaires during the sessions. A second venipuncture
will be planned after the end of treatment (month 6).
Interventions
In the Netherlands, cognitive behavioral therapy (CBT)
and interpersonal therapy (IPT) are the most frequently
practiced evidence- based psychological interventions
for depression. Both therapies are applied in weekly ses-
sions in routine clinical settings. CBT for depression is
based on the manual by Beck [1] and IPT is based on
the manual by Klerman [2]. The interventions will be of-
fered in the participating mental health centers. Partici-
pants in the experimental condition (twice-weekly
sessions) will receive 16 sessions during the first 8 weeks
of treatment, and 4 sessions during the last 8 weeks (up to
20 sessions during 16 weeks). Patients in the control
Fig. 2 Flow of participants
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condition (once-weekly sessions) will receive 16 sessions
during the first 16 weeks and 4 sessions during the last
8 weeks (up to 20 sessions during 24 weeks). Treatment
manuals are used for all interventions and both treatments
will contain 12 to 20 sessions of 45 minutes, depending
on the individual progress of the patients. Qualified
therapists who received additional training from prof.
Steven Hollon (CBT) and prof. Holly Swartz (IPT), ex-
perts in their respective modalities, will deliver the in-
terventions. Therapists participate in only one of the
therapy conditions (CT or IPT) and will consult each
other on current cases in biweekly consultation meet-
ings. The sessions will be videotaped.
Instruments
An overview of all patient instruments per assessment
is given in Table 1. An overview of therapist/observer
ratings per assessment is given in Table 2.
Instruments: clinical outcome measures
Depression: Beck Depression Inventory II (BDI-II) [37–39, 42]
The BDI is a 21-item self-report instrument assessing
depressive symptoms during the last two weeks. The
items are rated from 0 to 3, with 3 for the most
depressed mood. A score 0–13 indicates minimal de-
pression, 14–19 mild depression, 20–28 moderate de-
pression and 29–63 severe depression. The instrument
can be answered in 5–10 minutes. Several studies have
shown that the BDI-II also is a strong screening measure
for depression [37, 42].
Quality of life: EQ-5D(5 L) [43, 44]
The EQ-5D consists of five health state questions
(mood, symptoms of pain/discomfort, mobility, daily ac-
tivities, self-care) on which respondents indicate their
own health state on a scale from 0 (no problems) to 3
(severe problems) during the past week. In addition, pa-
tients will rate their overall health on a scale from 0
(worst possible health) to 100 (best possible health). The
Dutch EQ-5D (5 L) tariff will be used to calculate
Quality-Adjusted Life-Years (QALYs). The EQ-5D (5 L)
was validated for the Dutch population [44].
Remission of depression: remission of depression
questionnaire [45, 46]
The RDQ is a 41-item self-report questionnaire asses-
sing symptoms of depression as well as other variables
reported by patients as relevant to determining remis-
sion during the past week. The items are grouped into
7 domains: symptoms of depression (13 items), anxiety
and irritability (5 items), features of positive mental
health (11 items), coping ability (3 items), functioning
(3 items), life satisfaction (3 items), and a general
sense of wellbeing (3 items). Items are rated on a
3-point rating scale (not true (0) - always true (2)).
The questionnaire has shown excellent psychometric
qualities.
Quality of life: happiness question [47]
The question ‘If you were to consider your life in gen-
eral, how happy or unhappy would you say you are, on
the whole?’ can be rated on a 7-points scale (1 = com-
pletely unhappy – 7 = completely happy) and was used
in 33 nation surveys, including the Netherlands. The
happiness question (code = Code: O- HL/g/sq/v/7/a) was
used in many studies. In addition, we will ask a happi-
ness question focusing on the present day (‘How happy
of unhappy would you say you are today?’).
Rand-36 [48]
The RAND-36 is an 36-item assessment of general
health and disabilities and covers the following domains:
psychical and social functioning, role restriction due to
physical or emotional problems, mental health, energy,
pain, and general health perception. The RAND-36 has
shown to be a reliable, valid and sensitive measure [48].
Mood: mood question
Each session, patients will be asked to rate their current
mood on a 0 (worst mood) -10 scale (best mood).
Longitudinal Interview Follow-up Evaluation (LIFE) [49]
The LIFE is a semi-structured interview that will be used
by an independent rater to assess episodes and symp-
toms of depression retrospectively in the long-term
follow-up phase. The LIFE has shown reliable and valid
for characterizing the course of depression over the
period of one year [50, 51].
Instruments: cost-effectiveness
Trimbos/iMTA questionnaire for Costs associated with
Psychiatric Illness (TiC-P) – updated version 2012 [52]
Societal costs in the past three months will be mea-
sured using the TiC-P. The TiC-P consists of two dif-
ferent parts: part one (16 items) compromises costs
due to loss of production including absenteeism from
paid and unpaid work, and presenteeism. Part two
(4 items) focuses on use of (psychiatric) health care in-
cluding primary and secondary care, complementary
care and home care. For the valuation of health care
utilization standard prices [53] will be used. Medication
use will be valued using prices of the Royal Dutch Society
for Pharmacy [54].
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Table 1 Overview of patient instruments per time point (months)
Instruments 0 5 1 2 3 4 5 6 9 12 24
Clinical outcomes
Depression
Beck Depression Inventory II (BDI-II)1 x x x x x x x x x x x
Remission of Depression Questionnaire (RDQ) x x x x x x
Quality of life
RAND-36 x x x x x x x
EQ-5D(5L) x x x x x x
Happiness questiona x x x x x x x x x x x
Mood questiona x x x x x x x x x x x
Longitudinal Interval Follow-up Evaluation (LIFE) x x x x x x x x x x x
Cost-Effectiveness
Trimbos/iMTA questionnaire for Costs associated with
Psychiatric Illness - update version 2012 (TiC-P)
x x x x x x
Process/Predictors
-Therapy-specific-Therapist-patient relationship
Working Alliance Inventory (WAI) x x x x x x x
Motivation
Autonomous and Controlled Motivation for Treatment x x x x x x x x
Questionnaire (ACMTQ)
Compliance
Patient compliance ratings x x x x x x x x
Behavioral activation
Behavioral Activation for Depression Scale (BADS) x x x x x x x x
Automatic thoughts
Cognition Checklist (CCL) x x x x x x x x
Emotion regulation
Action Control Scale (ACS) x x
Childhood trauma





Competencies of Cognitive Therapy Scale (CCTS) x x x x
IPT Skills
IPT Skill Inventory x x x x
Executive functioning
N-back task x x x x
Biological markers x x
Brain-Derived Neurotrophic Factor (BDNF)
DNA methylation x x
Oxytocin x x
Other measures
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Instruments: moderators and mechanisms of change
Therapist-patient relationship: working alliance inventory-short
form [55–58]
The WAI intends to measure tasks (e.g. behaviors and
cognitions that form the therapeutic process), bonds
(e.g. positive personal attachments between patient and
therapist) and goals (e.g. therapist and patient mutually
endorsing and valuing the goals) as components of the
therapeutic alliance. The questionnaire consists of 12
items rated on a 5-point Likert scale and will be filled
out by both patient and therapist [59, 60]. All therapy
sessions will be videotaped. Independent experts will
rate the therapeutic alliance on a random selection of
videotapes using the 12-item Observer version of the
Working Alliance Inventory-Short (WAI-O-S). The
instrument has shown to have adequate psychometric
properties.
Motivation: autonomous and controlled motivation for
treatment questionnaire [61]
The ACMTQ includes two six-item subscale in order to
assess autonomous (identified; ‘I personally believe it is
the most important aspect of becoming well’ and inte-
grated; ‘Managing my depression allows me to partici-
pate in other important aspects of my life’) motivation
and controlled (external; ‘Others would be upset if I
didn’t” and introjective; ‘I would feel guilty if I didn’t do
what my therapist said’) motivation.
The format of the questionnaire was adapted from the
Treatment Self-Regulation Questionnaire (TRSQ; 61]. Pa-
tients are provided with a stem (‘I participate in therapy be-
cause’) and asked to rate twelve items on a 7-point rating
scale (1 = strongly disagree - 7 = strongly agree). Internal
consistency has been shown to be sufficient [62].
Compliance
Compliance will be operationalized as the amount of no-
shows (not showing up without leaving a message), can-
celled and replaced appointments. Patients will rate their
effort in treatment before each session. Furthermore, the
therapist will give a rating of patients compliance to the
therapy at the end of treatment on a 7-point scale.
Activation: behavioral activation for depression scale [63]
The BADS is a 25-item self-report scale that intends to
measure patients’ avoidance behavior and activity level
during the past week. The scale includes four subscales:
Activation, Avoidance/Rumination, Work- School and
Social Impairment. Items are rated on a 7-point scale.
Validity and reliability showed to be adequate [63].
Therapist adherence: collaborative study psychotherapy
rating scale [64]
In order to measure therapists adherence to the treat-
ment condition, independent raters will review a random
selection of sessions by rating 76 items on a seven-point
scale from the following subscales: Cognitive Behavioral
Therapy (e.g. cognitive rationale, assessing cognitive pro-
cesses, evaluating and changing beliefs, behavioral focus,
Table 1 Overview of patient instruments per time point (months) (Continued)
Demographics x
Diagnostics
Structured Clinical Interview for DSM-IV x
Axis I Disorder (SCID-I)/MINI-Plus
Attribution of therapy effects x
Treatment evaluation x
aDepressive symptoms, mood and happiness will be rated each session
Table 2 Overview of therapist/observer instruments per time
point (months)




Working Alliance Inventory- Therapist
(WAI-T)
x x x x x x
Working Alliance Inventory- Observer
(WAI-O)











Competencies of Cognitive Therapy
Scale-Therapist (CCTS-T)
x x x




Therapist-rated recall qualitya x x x x x x
Quality of recall will be assessed each sessiona
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homework and collaborative structure alternative cogni-
tive strategies and operant approaches), Interpersonal
Therapy (e.g. interpersonal rationale, focus on feelings,
assessing interpersonal relationships and tendencies,
assisting changes in interpersonal functioning, role tran-
sitions, interpersonal disputes, interpersonal deficits and
interpersonal therapy scale ), Facilitative Conditions and
Explicit Directiveness. Items regarding medication use
and clinical management were omitted. High internal
consistency and inter-rater reliability was reported [64].
Emotion Regulation: Action Control Scale 24 (ACS-24) [65, 66]
The ACS is a forced-choice self-report measure devel-
oped to assess differences in action-state orientation (the
ability to initiate and maintain intentions). Two scales of
the ACS will be used: action orientation subsequent to
failure vs. preoccupation (AOF, 12 items, e.g. the ability
to detach from thoughts about alternative goals or un-
desirable events that may interfere with progress on the
task at hand.) and prospective and decision-related action
orientation vs. hesitation (AOD, 12 items, e.g. the degree
to which individuals have difficulty initiating intended
goal-directed activities).
CT Skills: Competencies of Cognitive Therapy Scale-Self
Report (CCTS-SR) [67, 68]
Two versions of this report will be used: a 29-item pa-
tient version and a 9-item therapist version. Both mea-
sures were designed to assess patients’ mastery of CT
skills in the past two weeks. Patients rate the scale based
on their skill use on a 1 (not at all) to 7 (completely)
scale, while therapists evaluate a patient’s ability, inde-
pendence, and frequency of use of behavioral activation,
automatic thoughts, and core belief related CT strategies
on a scale from 0 (none) to 6 (extensive). Psychometric
properties seem promising [67].
Performance of CT Strategies (PCTS) [67]
Independent raters will assess the extent to which pa-
tients perform or intend to perform CT skills for a ran-
dom selection of tapped sessions. The scale consist of 15
items that are rated on a 6-point Likert scale focusing
on behavioral activation, automatic thought work, and
schema or core belief work. Internal consistence has
been shown to be sufficient [67].
IPT skill inventory
In order to explore the interpersonal skills the patients de-
velops during treatment the IPT skill Inventory was devel-
oped by two authors (SB and FP) of the present paper. The
questionnaire consists of 31 items that are rated on a
7-point Likert scale (not at all – completely). Items were
constructed by use of the following subscales: general
interpersonal skills (13 items), bereavement (4 items),
interpersonal conflict (5 items), interpersonal change
(5 items), and interpersonal deficiency (4 items). After
data collection, a factor analysis will be conducted in
order to investigate the structure of the questionnaire.
Recall
Each session, therapists will rate the degree to which the
patient seems to remember last session’s content on
10-point scale (0 = patient remembers nothing – 10 = pa-
tient remembers everything).
Maltreatment in childhood: Childhood Trauma
Questionnaire-Short Form (CTQ-SF) [69]
To assess maltreatment in childhood, the Childhood
Trauma Questionnaire-Short Form (CTQ-SF) is used.
The CTQ-SF is a 28-item retrospective self-report ques-
tionnaire designed to assess five types of negative child-
hood experiences: (1) emotional neglect, (2) emotional
abuse, (3) physical neglect, (4) physical abuse and (5)
sexual abuse. In addition, tendencies to minimize or
deny abuse experiences are measured. The truth of each
statement is rated on a 5-point scale. Adequate reliability
and validity has been shown [70, 71].
Automatic Thoughts: Cognition Checklist (CCL) [72]
The CCL investigates patients’ automatic thoughts and
cognitions related to anxiety and depression. The scale
consists of 26 items and is rated on a 5-point Likert
scale. Internal consistency and validity was supported.
Executive functioning: n-back task [73]
During the n-back task patients are asked if a letter on
the screen matches a letter previously (1-back, 2- back,
3-back) presented for 500 ms with an interval of
2000 ms. First, the patient will be asked to run a test
trial, where he will get elaborate feedback about the in-
correct responses (‘The previous letter was X, this indi-
cated you had to press the button’). Second, the patient
will complete a 1-back trial (two minutes) and a 2-back
trial (two parts of 2.5 minutes). Only when the patient
performs well on the 2-back (e.g. 2/3 correct responses;
a correct response means a correct press or a correct
no-press), he will be forwarded to the 3-back part of the
task that will also take five minutes (two parts of 2.5 mi-
nute). Amount of targets in each condition will be 33 %.
Feedback will be given after a correct response (marked
by a green V) or a miss (marked by a black X). Working
memory load increases as the task progresses from
1- back to 3-back and is suggested to require executive
processes. The task will take a maximum of 12.5 minutes.
Accuracy of responses (hits – false alarms) and reaction
times will be measured. To prevent fatigue of the online
assessments the patient will be asked to do the n-back
task at another day than the other questionnaires.
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Treatment preferences [74]
Patients preferences for either CT or IPT will be ques-
tioned before treatment by use of a 12-item question-
naire. A similar questionnaire was used in a previous
study and adapted for use in the current trial.
Instruments: biological measurements
Blood samples will be collected at baseline and after six
months at the research sites. Blood samples will be col-
lected using EDTA tubes (18 ml), serum tubes (6 ml)
and PAX gene tubes (2 ml). EDTA 3 ml tubes will be
sent to VUmc where DNA will be isolated followed by
analysis of CpG islands adjacent to promoters I and IV.
The serum tube, EDTA tubes (6 ml) and PAX tubes will
be stored (e.g. in VUmc or hospitals near to the research
locations) at −80 °C. After data collection (October
2016) all blood samples will be collected at VUmc. Use
of medication and alcohol/drugs use in 24 hours before
collecting the blood samples will be registered at base-
line and after six months.
Data-analyses
Data-analyses will include an intention-to-treat analysis
and additional subgroup analyses.
Data-analyses: primary outcome measures
Acute and long-term effects of the interventions (respect-
ively 6 and 12 months) will be analyzed using mixed re-
gression. This will enable us to use all outcome ratings
and fit the growth curve of time, enter separate levels for
study therapists and clinical sites, and also deal effectively
with missing values. Time to recovery and relapse (episode
of MDD after remission) and recurrence (episode of MDD
after recovery) in the course of follow-up (12 and
24 months) will be analyzed with Cox regression. In
addition, we will determine the proportion of patients that
show reliable and clinically significant improvement on
the outcome measures. Our calculations will be based on
the method of Jacobson and Truax [75] which prescribes
that Clinical Improvement (CI) is based on both Reliable
Change (RC), the extent to which the pre-to-post-differ-
ence score is reliable; and on Clinical Significant change
(CSC), the extent to which post-treatment scores are clin-
ically meaningful [76]. Although the major question of this
study focuses on the intensity of psychotherapy for de-
pression, this study will additionally explore whether the
effect of treatment intensity differs between IPT and CBT
by testing an interaction between treatment conditions.
Data-analyses: mechanisms of change
To identify mechanisms of change and the strength of
the factors involved, both multilevel models and struc-
tural equation models (SEM, using path analysis in
Mplus) will be used for mediation analyses. In a recent
paper, for example, we used a latent difference score
model to analyze mediation and temporality in the con-
text of an RCT [77].
Data-analyses: biological analyses
Levels of oxytocin, BDNF, methylation profile of the
BDNF gene (e.g. CpG I and IV) and RNA marker pro-
files will be analyzed after finishing data collection. Pre-
and post-treatment differences will be computed. The
predictive value of the methylation profile of the BDNF
gene (e.g. CpG I and IV) and RNA marker profiles on
treatment outcome will be investigated.
Data-analyses: cost-effectiveness
In order to evaluate cost-effectiveness a Cost Effective-
ness Analysis (CEA) and Budget Impact Analysis (BIA)
will be performed. Within the CEA the difference in so-
cietal costs (measured by the TiC-P at baseline and after
3, 6, 9 and 12 months) generated by patients in the two
conditions (two sessions versus one session a week) will
be related to the difference in clinical effects (measured
with the BDI-II and quality- adjusted life-years (QALYS)
based on the EQ-5D) over the course of twelve months.
Missing cost and effect data will be treated using mul-
tiple imputation. Bootstrapping with 5000 replications
will be used to estimate 95 % confidence intervals
around cost differences and the uncertainty surrounding
the ICERs. Uncertainty surrounding the ICERs will be
graphically presented on cost-effectiveness planes. Cost-
effectiveness acceptability curves [78] will also be esti-
mated. Adjustment for confounders and effect modifiers
will be done if necessary. In the budget impact analysis,
the effectiveness of interventions will be extrapolated
using a simple Markov model over a period of 5 years
based on the estimates obtained from the proposed
study. Societal, government (Budget Kader Zorg) and in-
surer perspectives will be considered. Different scenarios
will be evaluated including: 1) the intervention is not im-
plemented, 2) the intervention is offered to the whole
patient population, 3) the intervention is implemented
over a period of 4 years, and 4) the intervention is only
offered to subgroups of the potential patient population.
These subgroups will be defined based on the results of
the study, e.g. subgroups that particularly benefit from
the intervention. The total number of patients eligible
for the intervention will be estimated based on Dutch
incidence and prevalence rates of MDD. Resource
utilization is calculated by multiplying the number of eli-
gible patients with the resource utilization rates obtained
from the economic evaluation. Different prices will be
used to value resource use depending on the perspective
of the analysis. Both resource use and annual costs will
be presented over a 5-year period for all perspectives.
Aggregated and disaggregated total costs per year will be
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presented for the different perspectives and scenarios.
We expect that the largest economic benefits generated
by the intervention will be related to reduced productiv-
ity losses. A small effect will be expected on the number
of sessions needed for sustained recovery. Thus, there
will be an increased capacity at mental health institu-
tions to treat depressed patients. This will be taken into
account in the BIA as well.
Discussion
We presented a protocol for studying the session fre-
quency of psychotherapy. Furthermore, we focused on
the underlying change mechanisms in psychotherapy
and try to capture physiological processes that are hy-
pothesized to be involved during the course of depres-
sion and psychotherapy.
The finding that a higher session frequency leads to faster
and more improvement of depressive symptoms might lead
to adaptions in mental health care organization, where en-
hancing the session frequency may lead to shorter CBT and
IPT treatments and will optimize the (cost) effectiveness of
treatments for depression. In this case, not only patients’
suffering, but also the societal burden of depression can be
reduced. The finding that a greater session frequency leads
to a better and faster treatment outcome might give us
insight into the mechanisms of change. Actually, if we find
that a greater session frequency leads to better and faster
treatment outcomes, we can directly test if specific or non-
specific mechanisms of change explain the differences in
outcome. Furthermore, by investigating differences in
mechanisms of change between the different conditions we
might enhance knowledge about the mediating role of non-
specific factors and therapy specific factors in therapy. For
example, the finding that only patients who receive CBT
improve on the CBT skills will support the hypothesis that
learning CBT skills is a therapy-specific mechanism of
change. Insight in the mechanisms of change and physio-
logical processes underlying psychotherapy can further en-
able us to optimize treatments and help us understand
human functioning beyond the context of therapy [8].
This study is the first to investigate the hypothesis that,
while keeping total number of sessions equal, twice-weekly
sessions lead to better outcomes than once-weekly sessions
for depression in a head-to- head comparison. Further-
more, by including frequent assessments of hypothesized
mechanisms of change, the inclusion of moderators (to spe-
cify subsets of patients who respond to specific mecha-
nisms) and using advanced statistical techniques we hope
to provide the optimal conditions for detecting mechanisms
of change in psychotherapy for depression. Because patients
are randomized to type of therapy this study provides the
unique opportunity to compare differences between CBT
and IPT with regard to session frequency and the mecha-
nisms of change. Another strength of this study is the
inclusion of physiological assessments. Over the past de-
cades, there has been an increasing interest in a multidi-
mensional approach for understanding the various forms of
mental health disorders. It seems important to not only in-
vestigate mental disorders from self-reports or behavioral
observations but also to focus on the biological aspects, in-
cluding genetic and other molecular phenomena [15].
Hopefully, including physiological assessments in the study
protocol will contribute to a more comprehensive under-
standing of depression across the course of psychotherapy.
Trial status
The trial is in the on-going recruitment phase.
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